BGC > Produktsuche > Ursodeoxycholic acid | 128-13-2

Appearance	White or almost white powder
Solubility	Practically insoluble in water, freely soluble in ethanol (96 percent),slightly soluble in acetone, practically insoluble in methylene chloride
Identification	Infrared absorption, TLC and chrominance test
Melting point	About 202oC
Specific optical rotation	[α ]D20; +58.0o~+62.0o
Heavy metals	≤ 20PPM
Loss on drying	≤ 1.0%
Sulphated ash	≤ 0.1%
Residual solvents
Acetone	≤ 0.5%
Methanol	≤ 0.3%
Secondary Butyl Alcohol	≤ 0.5%
Assay (titration)	99.0%~101.0%(on the dried basis)
Related substance(TLC)
Lithocholic acid	≤ 0.1%
Cholic acid	≤ 0.5%
Chenodeoxycholic Acid	≤ 1.0%
Others	≤ 0.25%
Standard	EP grade
Content	99.0~101.0%
Capacity	10MT/month
Loading port	Shanghai
Use	Ursodeoxycholic acid, Used as an anticholelithogenic. Epimer with Chenodiol with respect to the hydroxyl group at C7.
Package	25kg/drum or according to the customers’ demand
Storage	Stored in the dry and ventilated inside storeroom, prevent direct sunlight, slightly pile and put down

Appearance:
White powder, odorless; Insoluble in water, easily soluble in 96% ethanol, slightly soluble in acetone, insoluble in dichloromethane.

Application:
Cholelithiolytic drugs. It is mainly used for cholesterol gallstones not suitable for surgical treatment, especially the gallbladder function is basically normal, stone diameter below 15mm, X-ray, non-calcified floating cholesterol stones with high cure rate. It also has certain therapeutic effect on toxic hepatitis, cholecystitis, primary sclerosing cholangitis and primary cholestatic cirrhosis. To improve the efficacy of α-interferon in the treatment of chronic hepatitis C. There are diarrhea, rare constipation, allergic reaction, itching, headache, dizziness, stomach pain, pancreatitis and bradycardia. Complete obstruction of biliary tract and severe liver dysfunction and
pregnant women should not use.

Molecular Fomula	C24H40O4
Molecular weight	392.57
Appearance	white powder
Assay	99%

Appearance	White or off-white powder
Lithocholic acid	≤ 0.1%
Single Impurity	≤ 0.1%
Total Impurities	≤ 1.5%
Assay	99.0 ~ 101.0%

Description:
Ursodeoxycholic acid (UDCS) is a cell protectant used extensively to mitigate hepatic and biliary diseases. Ursodeoxycholic acid may be used to study its specific activities that range from reduction of cholesterol absorpition, cholesterol gallstone dissolution to suppression of immune response.IC50: M1-family aminopeptidase: IC50 = 2.6 µM (Plasmodium falciparum 3D7); NTCP: IC50 = 3.6 µM (human); HCT-116: IC50 = >50 µM (human); GBM: IC50 = >50 µM (human) Asbt: Ki= 75 µM (human)

• Molecular Weight:392.57
• Boiling Point:547.1°C
• Melting Point:203-204 °C (lit.)
• Purity:≥ 99.0%

Molecular Formula:
C24H40O4
Canonical SMILES:
CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C
InChI:
1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1
InChIKey:
RUDATBOHQWOJDD-UZVSRGJWSA-N
Solubility:
Soluble in Ethanol (50 mg/ml)
Appearance:
White Crystal Powder
Application:
Gallstone-dissolving drugs; Anti-neoplastic; For the prevention and treatment of cholesterol gallstones; Reduces hydrophobic bile acids and decreases both lymphocyte reactivity and serum alkaline phosphatase levels,IC50: M1-family aminopeptidase: IC50 = 2.6 µM (Plasmodium falciparum 3D7); NTCP: IC50 = 3.6 µM (human); HCT-116: IC50 = >50 µM (human); GBM: IC50 = >50 µM (human) Asbt: Ki= 75 µM (human)
Storage: Store at RT
Synonyms:
5beta-cholanic acid-3alpha,7beta-diol; Actigall; ursodeoxycholate; ursodiol; Ursodeoxycholic acid